Sequantrix GmbH
Sequantrix is a biotechnology company focused on developing anti-fibrotic therapies. Leveraging one of the world's largest human multi-modal, single-cell datasets in fibrotic diseases, the company discovers and validates novel targets and develops drug candidates up to clinical proof of concept. Their proprietary FibroDecoder AI platform identifies and scores targets, which are then validated using human organoid-based disease models. Sequantrix aims to address the significant unmet medical need for effective anti-fibrotic treatments across various organ failures, including kidney, liver, and lung diseases.
Sequantrix GmbH
Sequantrix is a biotechnology company focused on developing anti-fibrotic therapies. Leveraging one of the world's largest human multi-modal, single-cell datasets in fibrotic diseases, the company discovers and validates novel targets and develops drug candidates up to clinical proof of concept. Their proprietary FibroDecoder AI platform identifies and scores targets, which are then validated using human organoid-based disease models. Sequantrix aims to address the significant unmet medical need for effective anti-fibrotic treatments across various organ failures, including kidney, liver, and lung diseases.